Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT06242834 | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 11 | Northwestern UniversityOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT01318317 | Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 8 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT01849263 | Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study(COBRA) | active not recruiting | Phase 2 | 150 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 11, 2026 | clinicaltrials |
| NCT03922724 | Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma | active not recruiting | Phase 2 | 91 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04571138 | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 35 | Seattle Children's HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04665765 | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04965155 | A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)(ISABEL) | active not recruiting | Phase 2 | 50 | EMN Trial Office S.r.l. Impresa SocialeOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 49 | GenmabINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05300282 | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients(FIL_A-BEGEV) | active not recruiting | Phase 1 / Phase 2 | 122 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06492837 | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients(FIL_MOZART) | active not recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Sep 11, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04124497 | A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients(DPd) | active not recruiting | Phase 2 | 45 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)(EPCORE™ NHL-3) | active not recruiting | Phase 1 / Phase 2 | 78 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome(EPCORE™ CLL-1) | active not recruiting | Phase 1 / Phase 2 | 194 | GenmabINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)(EPCORE™ NHL-2) | active not recruiting | Phase 1 / Phase 2 | 543 | GenmabINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT06311227 | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07387471 | Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | active not recruiting | Phase 2 | 14 | AbbVieINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04439136 | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03964090 | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | active not recruiting | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07081022 | JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 180 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02131584 | Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03824483 | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | active not recruiting | Phase 2 | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04624906 | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia(BRAWM) | active not recruiting | Phase 2 | 63 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03179917 | Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma | active not recruiting | Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05470777 | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL | active not recruiting | Phase 2 | 37 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05951959 | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma(TrAVeRse) | active not recruiting | Phase 2 | 108 | AstraZenecaINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06183489 | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma(ERASMM) | active not recruiting | Phase 2 | 50 | European Myeloma Network B.V.NETWORK | 4 | Sep 2, 2026 | clinicaltrials |
| NCT04262843 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | active not recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04315324 | Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | active not recruiting | Phase 1 / Phase 2 | 67 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06390852 | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) | active not recruiting | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05207670 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies(MorningSun) | active not recruiting | Phase 2 | 320 | Genentech, Inc.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04802590 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 210 | The Lymphoma Academic Research OrganisationOTHER | 3 | Aug 28, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04077723 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 498 | Hoffmann-La RocheINDUSTRY | 12 | Aug 27, 2026 | clinicaltrials |
| NCT00792948 | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06112847 | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03016871 | Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL | active not recruiting | Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04626791 | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | active not recruiting | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05761171 | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | active not recruiting | Phase 2 | 78 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT01297764 | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma(QUAD) | active not recruiting | Phase 1 / Phase 2 | 17 | Hackensack Meridian HealthOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03410875 | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05249959 | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.(FIL_COLUMN) | active not recruiting | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | active not recruiting | Phase 2 | 189 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 21, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials